Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20 µg versus 10 µg hepatitis B vaccine plus HBIG in high-risk infants
ChiCTR-PRC-09000459Phase 4Completed
- Sponsor
- Beijing YouAn Hospital
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant hepatitis B vaccine Bio Farma and hepatitis B immune globulin in hepatitis B (HBV) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoints: Hepatitis B surface antigen, Anti-HBs antibody concentrations and 1 more. Started Jun 2009; status: completed.
02
Drugs
recombinant hepatitis B vaccine Bio Farmahepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-PRC-09000459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-09000459.